Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Fountzilas, C. Nicolaides, D. Bafaloukos, A. Kalogera-Fountzila, H. Kalofonos, G. Samelis, G. Aravantinos, N. Pavlidis (2000)
Docetaxel and Gemcitabine in Anthracycline-Resistant Advanced Breast Cancer: A Hellenic Cooperative Oncology Group Phase II StudyCancer Investigation, 18
D. Mavroudis, N. Malamos, A. Alexopoulos, C. Kourousis, S. Agelaki, E. Sarra, A. Potamianou, Ch. Kosmas, G. Rigatos, T. Giannakakis, K. Kalbakis, F. Apostolaki, J. Vlachonicolis, S. Kakolyris, G. Samonis, V. Georgoulias (1999)
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.Annals of oncology : official journal of the European Society for Medical Oncology, 10 2
G. Kornek, K. Haider, W. Kwasny, M. Raderer, B. Schüll, T. Payrits, D. Depisch, E. Kovats, F. Lang, W. Scheithauer (2002)
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 5
P. Vici, P. Foggi, E. Capomolla (2002)
2002. Biweekly paclitaxel/gemcitabine as salvage treatment in breast cancer patients: preliminary resultsProc ASCO, 21
A. Murad, R. Guimarães, B. Aragão, A. Scalabrini‐Neto, V. Rodrigues, R. García (2001)
Phase II Trial of the Use of Paclitaxel and Gemcitabine as a Salvage Treatment in Metastatic Breast CancerAmerican Journal of Clinical Oncology, 24
F. Lenz, F. Beldermann, M. Geberth, G. Bastert, A. Schneeweiss (2003)
455 A phase II study of first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated, Her-2 negative metastatic breast cancer (MBC)Ejc Supplements, 1
D. Mavroudis, N. Malamos, A. Alexopoulos (1999)
1999. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trialAnn Oncol, 10
L. Laufman, C. Spiridonidis, J. Pritchard, R. Roach, J. Zangmeister, N. Larrimer, T. Moore, M. Segal, J. Jones, T. Patel, L. Gutterman, L. Carman, D. Colborn, J. Kuebler (2001)
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.Annals of oncology : official journal of the European Society for Medical Oncology, 12 9
R. Colomer, A. Llombart, A. Lluch, B. Ojeda, A. Barnadas, V. Carañana, Y. Fernández, L. Paz, V. Guillem, S. Alonso (2000)
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.Seminars in oncology, 27 1 Suppl 2
C. Delfino, G. Caccia, L. Gonzáles, E. Mickiewicz, J. Rodger, L. Balbiani, Daniel Morales, A. Comba, C. Brosio (2004)
Gemcitabine plus Paclitaxel as First-Line Chemotherapy for Patients with Advanced Breast CancerOncology, 66
Am J Cancer 2004; 3 Special issue 2: 19-20 REVIEW ARTICLE 1175-6357/04/0002-0019/$31.00/0 & Adis Data Information BV 2004. All rights reserved. Protocoles a base de gemcitabine et taxanes dans le cancer du sein Ramon Colomer Institut Catalan d’Oncologie, Gerone, Espagne La gemcitabine a suscite´ un vaste inte´reˆt expliquant son poı¨e´tique du fait de sa tole´rance he´matologique qui de´pend des e´valuation en situation me´tastatique en combinaison avec la doses et des sche´mas. majeure partie des agents disponibles et prochainement en Plusieurs essais de phase II ont e´tudie´ l’administration toutes adjuvant. Dans cet article, nous pre´sentons les re´sultats d’autres les deux ou trois semaines de la gemcitabine en association au [7-12] ` ` ere eme sche´mas d’administration hebdomadaire ou bi-mensuel de gem- paclitaxel. Les taux de re´ponses objectives en 1 et 2 citabine-paclitaxel ou gemcitabine-doce´taxel. ligne sont e´leve´s comme l’illustre le tableau II. De plus, la L’association de gemcitabine-doce´taxel a e´te´e´tudie´e selon tole´rance est bonne avec peu de toxicite´s de grade 3–4 : 2 a`7 % de diffe´rents sche´mas en administration a` J1, J8 J15 ou toutes les neutrope´nie fe´brile et 4 a` 8 % de thrombope´nie. [1-6] ere ` eme ` 2–3 semaines (J1, J15). Cette association en 1
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.